Monster Burner

• MONSTER BURNER — Monster Labs
• Brand: Monster Labs
• Category: High-stim thermogenic / stimulant-synergy research compound
• Content: 90 capsules
• Per Capsule (Label): Ephedrine 50 mg · Caffeine 250 mg · Aspirin 100 mg · 1,3-DMAA 90 mg
• Manufactured in: Cyprus
• Research Notice: For research/analytical use only. Not for human or veterinary consumption.

Product Overview

Monster Burner is a high-stimulus capsule designed around the classic

ECA (Ephedrine + Caffeine + Aspirin) framework with the addition of

1,3-DMAA, a potent indirect sympathomimetic.

Its purpose in laboratory settings is to support research on:

• thermogenesis and energy expenditure
• adrenergic pathway activation
• stimulant stacking/synergy models
• pre-exercise arousal and alertness mechanisms
• appetite and satiety perception signaling

The formula provides a clear and predictable active profile suitable for comparative analyses in metabolic, neurochemical, and stimulant-effect research workflows.

Key Research Highlights

Ephedrine:

Indirect -adrenergic agonist norepinephrine release lipolysis, thermogenesis, enhanced energy expenditure.

RCTs show modest short-term weight-loss effects when paired with caffeine.

Caffeine:

Adenosine A1/A2A receptor antagonist CNS arousal, lipolysis, thermogenesis; widely studied in metabolic and performance domains.

Aspirin:

COX enzyme inhibitor; historically added to prolong adrenergic effects (evidence mixed). Included in classical “ECA” models.

DMAA (1,3-dimethylamylamine):

Potent indirect sympathomimetic norepinephrine release; increases arousal, focus, cardiovascular activation.

Regulatory agencies classify DMAA as not lawful in U.S. dietary supplements.

Mechanism of Action (Simplified)

• Ephedrine: Increases NE release -adrenergic activation thermogenesis and fat mobilization.
• Caffeine: Blocks adenosine receptors enhances alertness and metabolic rate.
• Aspirin: Inhibits prostaglandin synthesis; historically included in ECA triads.
• DMAA: Strong CNS stimulant acting via indirect catecholamine modulation.

These combined pathways create a strong stimulant and thermogenic signal suitable for controlled laboratory comparisons with caffeine-only or ephedrine-only models.

Technical Specification Table

Field

Data

Per-Capsule Actives

Ephedrine 50 mg · Caffeine 250 mg · Aspirin 100 mg · DMAA 90 mg

• Pharmacology
• Ephedrine: indirect -agonist
• Caffeine: adenosine antagonist
• Aspirin: COX inhibitor
• DMAA: indirect sympathomimetic

Evidence Snapshot (ECA)

8-week RCT: ECA modestly greater weight reduction vs. placebo (short-term data)

• Doping Status
• Ephedrine: prohibited in-competition above 10 µg/mL
• DMAA: prohibited stimulant

• U.S. Regulatory
• Ephedrine alkaloids banned in dietary supplements;
• DMAA not lawful in supplements (FDA)

Origin

Cyprus

Research Background

• ECA trial: RCT (8 weeks) demonstrated increased metabolic output and moderate weight reduction compared with placebo.
• Thermogenic literature: Caffeine shown to activate brown adipose pathways and increase metabolic rate.
• Regulatory alerts: FDA prohibits ephedrine alkaloids and classifies DMAA as unlawful in supplements.

Potential Side Effects (Class-Based Literature)

• Palpitations, tachycardia, elevated blood pressure
• Anxiety, tremor, insomnia, agitation
• Nausea, headache, GI upset
• Risk heightened when combining stimulants or exceeding serving sizes
• Serious adverse events reported in rare cases with ephedrine/DMAA

Compliance & Legal Status

Regulatory:

Ephedrine alkaloids banned in U.S. dietary supplements; DMAA not lawful in supplements.

Local restrictions apply—check your jurisdiction before acquisition or study.

Anti-Doping:

• Ephedrine prohibited in-competition >10 µg/mL urine.

• DMAA prohibited as a stimulant.

Competitive athletes must avoid exposure.

Research-only:

Product supplied exclusively for laboratory/analytical evaluation. Not for human consumption.

Important Notice

For research use only. Not a medicine, not a dietary supplement, not for performance enhancement.

No human use is implied. Users are responsible for adherence to local laws, safety protocols, and anti-doping rules.